Arbeitsgruppe Ösophagus-/Magen-Karzinome - Studien
| Stadium II/III Adenokarzinom des Magens oder gastroösophagealen Übergangs – neoadjuvante/ perioperative Therapie |
| AIO-assoziierte Studie | www.clinicaltrials.gov |
zur Studie | ||
| AIO-STO-0315/ass: Perioperative RAMucirumab in combination with FLOT versus FLOT alone for reSEctable eSophagogastric adenocarcinoma - A phase II/III trial of the AIO (RAMSES / FLOT7) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-STO-0215: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of AIO/CAO-V/CAOGI (RENAISSANCE / FLOT5) Weitere Informationen zur Studie finden Sie hier! Pressemitteilung zur RENAISSANCE-Studie mehr |
||||
| ---in Rekrutierung; weitere Zentren nur auf Anfrage --- | ||||
| AIO-Studie | www.clinicaltrials.gov |
zur Studie | ||
| AIO-STO-0317: A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039) - DANTE-Trial | ||||
| ---in Rekrutierung--- | ||||
| Locally advanced, resectable adenocarcinoma of the esophagogastric junction |
| AIO-Studie | Für weitere Zentren offen |
zur Studie | ||
| AIO-STO-0118: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) - A randomized phase III joint study of the AIO, ARO and DGAV (RACE-trial) | ||||
| ---in Vorbereitung, Studienstart noch offen--- | ||||
| Lokal fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder gastroösophagealen Übergangs - palliative Therapie, 1st-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-YMO-0111/STO: Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer (MATEO = maintenance Teysuno in esophagogastric carcinoma) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0217: Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma The randomized phase 2 INTEGA trial. |
||||
| ---in Rekrutierung--- |
||||
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0417: Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - The randomized phase 2 MOONLIGHT trial. (A study of the AIO) | ||||
| ---in Rekrutierung--- | ||||
| Lokal
fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder
gastroösophagealen Übergangs - palliative Therapie, 2nd-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-STO-0415: A randomized, open label phase II trial of Irinotecan / Folinic Acid / 5-FU plus Ramucirumab versus Paclitaxel plus Ramucirumab in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy (RAMIRIS) | ||||
| ---in Rekrutierung--- | ||||
| Metastasiertes/fortgeschrittenes Magenkarzinom, Second-Line (2nd Line) |
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrialsregister.eu | zur Studie | |
| AIO-STO-0218: Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO (The RAP Trial) |
||||
| ---in Rekrutierung--- | ||||
| Plattenepithelkarzinom des Ösophagus, Zweitlinientherapie |
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-STO-0216/ass: A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs – The RAMOS study | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-STO-0117: A multicenteR open-label phase II triAl to evaluate NivoluMab and Ipilimumab fOr 2nd line therapy in elderly patieNts with advanced esophageal squamous cell cAncer [RAMONA] | ||||
| ---in Rekrutierung--- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 18.12.2018 |